betacorton creme
galderma sa - halcinonidum, ureum - creme - halcinonidum 1 mg, ureum 50 mg, antiox.: e 320, conserv.: triclosanum, chlorhexidini dihydrochloridum, excipiens ad-salbe für 1 g. - nicht infizierte, entzündliche dermatosen - synthetika
betacorton fettcrème
galderma sa - halcinonidum, ureum - fettcrème - halcinonidum 1 mg, ureum 100 mg, conserv.: triclosanum, chlorhexidini dihydrochloridum, excipiens ad-salbe für 1 g. - nicht infizierte, entzündliche dermatosen - synthetika
betacorton s lösung
galderma sa - halcinonidum, acidum salicylicum - lösung - halcinonidum 1 mg, säure-salicylicum 20 mg, alcohol isopropylicus, antiox.: e 320, excipiens ad-lösung für 1 ml. - nicht infizierte, entzündliche hyperkeratotische und schuppende dermatosen an behaarten körperstellen - synthetika
enhertu
daiichi sankyo europe gmbh - trastuzumab deruxtecan - brustgeschwulste - antineoplastische mittel - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.
tetravac injektionssuspension
sanofi pasteur europe - bordetella pertussis; clostridium tetani (auszug, produkte); corynebacterium diphtheriae (auszug, produkte); poliomyelitisvirus - diphtherie-pertussis-po
pentavac pulver und suspension zur herstellung einer injektionslösung
sanofi pasteur msd snc - bordetella pertussis; clostridium tetani (auszug, produkte); corynebacterium diphtheriae (auszug, produkte); haemophilus spec. (auszug, produkte); poliomyelitisvirus - diphtherie-haemophilus-
enhertu 100 mg pulver für ein konzentrat zur herstellung einer infusionslösung
daiichi sankyo (schweiz) ag - trastuzumabum deruxtecanum - pulver für ein konzentrat zur herstellung einer infusionslösung - praeparatio cryodesiccata: trastuzumabum deruxtecanum 100 mg, saccharum, histidinum, histidini hydrochloridum monohydricum, polysorbatum 80, pro vitro. - brustkrebs - biotechnologika
amorolfin dermapharm 50 mg/ml wirkstoffhaltiger nagellack
dermapharm aktiengesellschaft (3326989) - amorolfinhydrochlorid - wirkstoffhaltiger nagellack - teil 1 - wirkstoffhaltiger nagellack; amorolfinhydrochlorid (23522) 55,74 milligramm
tromphyllin retard 600
trommsdorff gmbh & co. kg (3086350) - theophyllin - retardtablette - teil 1 - retardtablette; theophyllin (00323) 600 milligramm
tromlipon 600 filmtabletten
trommsdorff gmbh & co. kg (3086350) - thioctsäure - filmtablette - teil 1 - filmtablette; thioctsäure (02117) 600 milligramm